Myogenic induced adipose-derived stem cells sheets combined with electrospun scaffolds of silk fibroin and poly(lactide-co-glycolide) for stress urinary incontinence treatment.
Liu M., Li Y., Zhao Y., Sun F., Lu Y., Wu J.
Animal Study, published in J Mol Histol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Mol Histol (2025)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40926179
- DOI
- 10.1007/s10735-025-10531-2
Abstract (original English)
The stress urinary incontinence (SUI) is a difficulty in urology and current sub-urethral sling treatments are associated with inflamation and recurrence. In this study, we developed a novel tissue-engineered sling with myogenic induced adiposederived stem cells (MI-ADSCs) sheets induced by 5-Aza and combined with electrospun scaffolds of silk fibroin and poly(lactide-co-glycolide) (SF/PLGA) for the treatment of stress urinary incontinence. MI-ADSCs increased α-SMA, MyoD and Desmin the mRNA and protein expression. ICG001, a specific inhibitor of β-catenin signaling pathway, could inhibit 5-Aza-induced expression of myoblast genes and proteins. Electrospun scaffolds of SF/PLGA (50/50) showed favorable mechanical properties and the biocompatibility. The MI-ADSCs sheets was combined with electrospun scaffolds of SF/PLGA (50/50) to form a novel tissue-engineered sling. The tissue-engineered sling was transplanted into female SUI rats to evaluate the feasibility and effcacy for the treatment of SUI. The tissue-engineered sling with MI-ADSCs sheets combined with SF/PLGA can restore leak point pressure (LPP) in the model of SUI steadily. It is of great potential to be a novel tissue-engineered sling in the treatment of SUI.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.